Evaluation of predictors of the development of azotemia in cats

Journal of Veterinary Internal Medicine

Volumn 23, Issue 4, 2009, Pages 806-813

  Jepson, R E ^a   Brodbelt, D ^a   Vallance, C ^b   Syme, H M ^a   Elliott, J ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b WALTHAM CENTRE FOR PET NUTRITION   (United Kingdom)

Author keywords

Cat; Chronic renal failure; Kidney; Renal; Urinary tract

Indexed keywords

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; BLOOD PRESSURE; CAT; CAT DISEASE; FEMALE; LONGITUDINAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOLOGY; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; UREMIA; URINE;

ANIMALS; AZOTEMIA; BLOOD PRESSURE; CAT DISEASES; CATS; FEMALE; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS;

ANIMALIA;

EID: 67749114178     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2009.0339.x     Document Type: Article

References (51)

1. Lulich JP, Osborne CA, O'Brien TD, et al. Feline renal failure: Questions, answers, questions. Compend Contin Educ Pract Vet 1992; 14: 127-152.
2. Dibartola SP, Rutgers HC, Zack PM, et al. Clinicopathologic findings associated with chronic renal disease in cats: 74 cases (1973-1984). J Am Vet Med Assoc 1987; 190: 1196-1202.
3. Elliott J, Barber PJ. Feline chronic renal failure: Clinical findings in 80 cases diagnosed between 1992 and 1995. J Small Anim Pract 1998; 39: 78-85.
4. Ross SJ, Osborne CA, Kirk CA, et al. Clinical evaluation of dietary modification for the treatment of spontaneous chronic kidney disease in cats. J Am Vet Med Assoc 2006; 229: 949-957.
5. Ross LA, Finco DR. Relationship of selected clinical renal function tests to glomerular filtration rate and renal blood flow in cats. Am J Vet Res 1981; 42: 1704-1711.
6. Ishani A, Grandits GA, Grimm RH, et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and haematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 2006; 17: 1444-1452.
7. Iseki C, Ikemiya Y, Kinjo K. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004; 65: 1870-1876.
8. Iseki K, Ikemiya Y, Iseki C, et al. Haematocrit and the risk of developing end-stage renal disease. Nephrol Dial Transplant 2003; 18: 899-905.
9. Brown SA, Crowell WA, Brown CA, et al. Review: Pathophysiology and management of progressive renal disease. Vet J 1997; 154: 93-109.
10. Ritz E, Gross ML, Dikow R. Role of calcium-phosphorus disorders in the progression of renal failure. Kidney Int 2005;68: S66-S70.
11. Locatelli F, Marcelli D, Comelli M, et al. Proteinuria and blood pressure as causal components of progression to end stage renal disease. Nephrol Dial Transplant 1996; 11: 461-467.
12. Iseki K, Ikemiya Y, Iseki C, et al. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003b;63:1468-1474.
13. Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community based population: A 10-year follow-up study. Kidney Int 2007; 71: 159-166.
14. Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community based population. J Am Med Assoc 2004; 291: 844-850.
15. Obermayr RP, Temml C, Knechtelsdorfer M, et al. Predictors of new onset decline in kidney function in a general middle-European population. Nephrol Dial Transplant 2007; 23: 1265-1273.
16. Muntner P, Coresh J, Smith JC. Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communi-ties study. Kidney Int 2000; 58: 293-301.
17. Schaeffner ES, Kurth T, Curhan GC. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084-2091.
18. Sato R, Soeta S, Syuto B, et al. Urinary excretion of N-acetyl-β-D-glucosaminidase and its isoenzymes in cats with urinary disease. J Vet Med Sci 2002; 64: 367-371.
19. Uechi M, Uechi H, Nakayama T, et al. The circadian variation of urinary N-acetyl-β-D-glucosaminidase and gamma-glutamyl-transpeptidase in clinically healthy cats. J Vet Med Sci 1998; 60: 1033-1034.
20. Lapointe C, Belanger MC, Dunn M, et al. N-acetyl-β-D-glucosaminidase index as an early biomarker for chronic kidney disease in cats with hyperthyroidism. J Vet Intern Med 2008;22: 1103-1110.
21. Syme HM, Markwell PJ, Pfeiffer D, et al. Survival of cats with naturally occurring chronic renal failure is related to severity of proteinuria. J Vet Intern Med 2006; 20: 528-535.
22. Kuwahara Y, Ohba Y, Kitoh K, et al. Association of laboratory data and death within one month in cats with chronic renal failure. J Small Anim Pract 2006; 47: 446-450.
23. Syme HM, Barber PJ, Markwell PJ, et al. Prevalence of systolic hypertension in cats with chronic renal failure at initial evaluation. J Am Vet Med Assoc 2002; 220: 1799-1804.
24. Matteucci E, Pellegrini L, Uncini-Manganelli C, et al. More on effects of storage time and temperature on urinary enzymes: A 1-year study. Enzyme 1992; 46: 249-251.
25. Field A. Discovering Statistics Using SPSS for Windows. Beverly Hills, CA: Sage Publications; 2003.
26. Hosmer DW, Lemeshow S. Applied Survival Statistics: Regression Modeling of Time to Event Data. New York: John Wiley and Sons; 1999.
27. Elliott J. Staging chronic kidney disease. In: Elliott J, Grauer GF, eds. BSAVA Manual of Canine and Feline Nephrology and Urology, 2nd ed. India: Replika Press Pvt Ltd; 2007:163.
28. Altman DG. Practical Statistics for Medical Research, 2nd ed. London: Chapman and Hall; 1991.
29. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-S266.
30. Verhave JC, Gansevoort RT, Hillege HL, et al. PREVEND study group: An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int 2004;66:S18-S21.
31. Domronkitchaiporn S, Sritara P, Kitiyakara C, et al. Risk factors for development of decreased kidney function in a southeast Asian population: A 12-year cohort study. J Am Soc Nephrol 2005; 16:791-799.
32. Belew AM, Barlett T, Brown SA. Evaluation of white-coat effects in cats. J Vet Intern Med 1999; 13: 134-142.
33. Pontremoli R, Cheli V, Sofia A, et al. Prevalence of micro-and macroalbuminuria and their relationship with other cardiovascular risk factors in essential hypertension. Nephrol Dial Transplant 1995; 10: 6-9.
34. Bigazzi R, Bianchi S, Campese V, et al. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension. Nephron 1992; 61: 94-97.
35. Brantsma AH, Bakker SJL, de Zeeuw D, et al. Urinary albumin excretion as a predictor of the development of hypertension in the general population. J Am Soc Nephrol 2006; 17: 331-335.
36. Hillege HL, Fidler V, Diercks GF, et al. Prevention of renal and vascular end stage disease (PREVEND) study group. Urinary albumin excretion predicts cardiovascular and non-cardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
37. Klausen KP, Scharling H, Jensen G, et al. New definition of microalbuminuria in hypertensive subjects: Association with incident coronary heart disease and death. Hypertension 2005;46: 33-37.
38. Jensen J, Henik RA, Brownfield M, et al. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease. Am J Vet Res 1997; 58: 535-540.
39. Mishina M, Watanabe G, Fujii K, et al. Non-invasive blood pressure measurements in cats: Clinical significance of hypertension associated with chronic renal failure. J Vet Med Sci 1998; 60: 805-808.
40. Javadi S, Djajadiningrat-Laanen SC, Kooistra HS, et al. Primary hyperaldosteronism, a mediator of progressive renal disease in cats. Domest Anim Endocrinol 2005; 28: 85-104.
41. Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985;249:F324-F337.
42. Hostetter TH, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 1981;241:F85-F92.
43. Brown SA, Brown CA. Single-nephron adaptations to partial renal ablation in cats. Am J Physiol 1995;269:R1002-R1008.
44. Ross SJ, Osborne CA, Lekcharoensuk C, et al. A case control study of the effects of nephrolithiasis in cats with chronic kidney disease. J Am Vet Med Assoc 2007; 230: 1854-1859.
45. Lawler DF, Evans RH, Chase K, et al. The aging feline kidney: A model mortality antagonist? J Feline Med Surg 2006; 8: 363-371.
46. Jepson RE, Brodbelt D, Elliott J, et al. Evaluation of the effects of control of systolic blood pressure on survival in cats with systemic hypertension. J Vet Intern Med 2007; 21: 402-409.
47. Kloke HJ, Branten AJ, Huysmans FT, et al. Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefits of calcium channel blockers? Kidney Int 1998; 53: 1559-1573.
48. Okazaki K, Oba K, Nakano H, et al. Urinary N-acetyl-β-D glucosaminidase activity predicts development of diabetic nephropathy. Geriatr Gerontol Int 2005; 5: 22-28.
49. Westhuyzen J, Endre ZU, Reece G, et al. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transplant 2003;18: 543-551.
50. Bosomworth MP, Aparicio SR, Hay AWM. Urine N-acetyl-β-D-glucosaminidase-A marker of tubular damage? Nephrol Dial Transplant 1999; 14: 620-626.
51. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456.